Top-News

Sandoz Group Aktie News

Aktie
WKN:  A3ETYB ISIN:  CH1243598427 US-Symbol:  SDZXF Branche:  Pharmazeutika Land:  Schweiz
57,98 CHF
+0,96 CHF
+1,68%
61,946 € 15:12:06 Uhr
Depot/Watchlist
Marktkapitalisierung *
26,14 Mrd. €
Streubesitz
46,68%
KGV
-
Dividende
0,60 CHF
Dividendenrendite
1,04%
neu: Nachhaltigkeits-Score
58 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 17,74: MM8UL8
Werbung

Sandoz Group News

15.04.25 - GlobeNewswire
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
All proposals of Board of Directors approved Gilbert Ghostine re-​elected as Chairman of Board of Directors; all other Board members standing for re-​election confirmed Dividend of ...
14.04.25 - GlobeNewswire
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” ...
14.04.25 - GlobeNewswire
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
31.03.25 - GlobeNewswire
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
MEDIA RELEASE NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN
12.03.25 - wallstreetONLINE Redaktion
Novo Nordisk vs. Hikma: Novo Nordisk: Wer macht das Rennen? – Das Original oder Generika?
Semaglutid heißt der Wunderstoff, der hinter Ozempic und Wegovy von Novo Nordisk steckt. In einigen Ländern läuft 2026 der Patentschutz für Semaglutid aus. Wie schwer wird das ...
05.03.25 - GlobeNewswire
Sandoz reports strong FY 2024 results and Q4 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
24.02.25 - GlobeNewswire
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
03.02.25 - GlobeNewswire
Francisco Ballester to retire; Peter Stenico appointed President Region International
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
14.01.25 - GlobeNewswire
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
MEDIA RELEASE
17.12.24 - GlobeNewswire
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »